Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

14 arms have a reported figure in this set.

B7-H4-directed ADC 2

EGFR x MET bispecific antibody 1

Amivantamab

Amivantamab

not stated in source · Single arm

ACC (n = 21)

responders: 1 patients (of 21), results posted 05.08.2026

Amivantamab in ACC · NCT05074940

gamma secretase inhibitor 2

Osugacestat (AL101, BMS-906024)

AL101 4 mg

4 mg · Single arm

R/M ACC with NOTCH1 to 4 activating mutation (n = 45)

responders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024

ACCURACY · NCT03691207

multi-kinase TKI 1

MYB mRNA degrader 1

REM-422

REM-422 24 mg (RP2D), biomarker positive

24 mg · Single arm

R/M ACC, MYB biomarker positive at RP2D (n = 7)

objective response rate: 43%, cutoff 01.07.2026, Abstract 6009 states 42% (3 of 7)

ARIA · NCT06118086

MYB splicing modulator 1

RGT-61159

RGT-61159 at or below RP2D

at or below RP2D (mixed doses) · Single arm

R/R ACC, evaluable (n = 39)

partial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pending

RGT-61159 Phase 1a/b · NCT06462183

VEGFR multi-kinase TKI 3

Lenvatinib (off Label)

Lenvatinib 24 mg

24 mg · Single arm

R/M salivary ACC (n = 26 evaluable)

objective response rate: 11.5%, primary analysis

ACC-LEN14 · NCT02860936

VEGFR TKI 2

VEGFR2 TKI 1

Rivoceranib

Rivoceranib 700 mg

700 mg · Single arm

R/M ACC (n = 80; 72 evaluable)

objective response rate (investigator): 15.3%, primary analysis

objective response rate (independent review): 9.7%, primary analysis

Rivoceranib Phase 2 · NCT04119453

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.